Rhythm Pharmaceuticals’ (RYTM) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research note published on Tuesday,Benzinga reports. They currently have a $80.00 price target on the stock, up from their prior price target of $70.00. A number of other equities analysts have also weighed in on the company. Needham […]
HC Wainwright reiterated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research note published on Tuesday,Benzinga reports. They currently have a $80.00 price target on the stock, up from their prior price target of $70.00. A number of other equities analysts have also weighed in on the company. Needham […]